These PD-1+ TAMs adopt an M2-like phenotype, directly engaging PD-L1–expressing tumor cells and secreting IL-10, thereby inhibiting CD8+ T cell proliferation and effector function (63, 64). This evidence concerns the gene IL10 and neoplasm.